These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 21632498)

  • 1. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system.
    Röllig C; Bornhäuser M; Thiede C; Taube F; Kramer M; Mohr B; Aulitzky W; Bodenstein H; Tischler HJ; Stuhlmann R; Schuler U; Stölzel F; von Bonin M; Wandt H; Schäfer-Eckart K; Schaich M; Ehninger G
    J Clin Oncol; 2011 Jul; 29(20):2758-65. PubMed ID: 21632498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.
    Mrózek K; Marcucci G; Nicolet D; Maharry KS; Becker H; Whitman SP; Metzeler KH; Schwind S; Wu YZ; Kohlschmidt J; Pettenati MJ; Heerema NA; Block AW; Patil SR; Baer MR; Kolitz JE; Moore JO; Carroll AJ; Stone RM; Larson RA; Bloomfield CD
    J Clin Oncol; 2012 Dec; 30(36):4515-23. PubMed ID: 22987078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
    Boddu PC; Kadia TM; Garcia-Manero G; Cortes J; Alfayez M; Borthakur G; Konopleva M; Jabbour EJ; Daver NG; DiNardo CD; Naqvi K; Yilmaz M; Short NJ; Pierce S; Kantarjian HM; Ravandi F
    Cancer; 2019 Apr; 125(7):1091-1100. PubMed ID: 30521114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival of Brazilian acute myeloid leukemia patients according to the European LeukemiaNet prognostic scoring system: a cross-sectional study.
    Datoguia TS; Velloso EDRP; Helman R; Musacchio JG; Salvino MA; Soares RA; Higashi M; Fadel AV; E Silva RSA; Hamerschlak N; Santos FPS; Campregher PV
    Med Oncol; 2018 Sep; 35(11):141. PubMed ID: 30187210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients.
    Tsai CH; Yao CY; Tien FM; Tang JL; Kuo YY; Chiu YC; Lin CC; Tseng MH; Peng YL; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
    EBioMedicine; 2019 Feb; 40():240-250. PubMed ID: 30662003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.
    Oran B; Jimenez AM; De Lima M; Popat UR; Bassett R; Andersson B; Borthakur G; Bashir Q; Chen J; Ciurea SO; Jabbour E; Cortes J; Kebriaei P; Khouri IF; Qazilbash MH; Ravandi F; Rondon G; Lu X; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1405-1412. PubMed ID: 25840338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
    Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
    Herold T; Rothenberg-Thurley M; Grunwald VV; Janke H; Goerlich D; Sauerland MC; Konstandin NP; Dufour A; Schneider S; Neusser M; Ksienzyk B; Greif PA; Subklewe M; Faldum A; Bohlander SK; Braess J; Wörmann B; Krug U; Berdel WE; Hiddemann W; Spiekermann K; Metzeler KH
    Leukemia; 2020 Dec; 34(12):3161-3172. PubMed ID: 32231256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia.
    Alpermann T; Kern W; Schnittger S; Schmid C; Kreuzer KA; Serve H; Pielken HJ; Schmitz N; Wendtner CM; Haferlach C; Haferlach T
    Leuk Res; 2013 Feb; 37(2):197-200. PubMed ID: 23237559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience.
    Benicio MTL; Ribeiro AFT; Américo AD; Furtado FM; Glória AB; Lima AS; Santos SM; Xavier SG; Lucena-Araujo AR; Fagundes EM; Rego EM
    Leuk Res; 2017 Sep; 60():109-114. PubMed ID: 28777950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine.
    Kim M; Ahn SY; Kim T; Jung SH; Song GY; Yang DH; Lee JJ; Kim MY; Park JH; Shin MG; Ahn JS; Kim HJ; Kim DDH
    Hematology; 2024 Dec; 29(1):2324417. PubMed ID: 38433437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
    Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation.
    Hemmati PG; Vuong LG; Terwey TH; Jehn CF; le Coutre P; Penack O; Na IK; Dörken B; Arnold R
    Eur J Haematol; 2017 Feb; 98(2):160-168. PubMed ID: 27706846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.
    Chretien AS; Fauriat C; Orlanducci F; Rey J; Borg GB; Gautherot E; Granjeaud S; Demerle C; Hamel JF; Cerwenka A; von Strandmann EP; Ifrah N; Lacombe C; Cornillet-Lefebvre P; Delaunay J; Toubert A; Arnoulet C; Vey N; Olive D
    Oncotarget; 2017 Jul; 8(30):49548-49563. PubMed ID: 28548938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Hansen DK; Kim J; Thompson Z; Hussaini M; Nishihori T; Ahmad A; Elmariah H; Faramand R; Mishra A; Davila ML; Khimani F; Lazaryan A; Sallman D; Liu H; Perez LE; Fernandez H; Nieder ML; Lancet JE; Pidala JA; Anasetti C; Bejanyan N
    Transplant Cell Ther; 2021 Mar; 27(3):256.e1-256.e7. PubMed ID: 33781526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
    Lo MY; Tsai XC; Lin CC; Tien FM; Kuo YY; Lee WH; Peng YL; Liu MC; Tseng MH; Hsu CA; Chen JC; Lin LI; Sun HI; Chuang YK; Ko BS; Tang JL; Yao M; Chou WC; Hou HA; Tien HF
    Am J Hematol; 2023 May; 98(5):760-769. PubMed ID: 36861732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
    Gaidzik VI; Schlenk RF; Paschka P; Stölzle A; Späth D; Kuendgen A; von Lilienfeld-Toal M; Brugger W; Derigs HG; Kremers S; Greil R; Raghavachar A; Ringhoffer M; Salih HR; Wattad M; Kirchen HG; Runde V; Heil G; Petzer AL; Girschikofsky M; Heuser M; Kayser S; Goehring G; Teleanu MV; Schlegelberger B; Ganser A; Krauter J; Bullinger L; Döhner H; Döhner K
    Blood; 2013 Jun; 121(23):4769-77. PubMed ID: 23632886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
    Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
    Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
    Hoff FW; Blum WG; Huang Y; Welkie RL; Swords RT; Traer E; Stein EM; Lin TL; Archer KJ; Patel PA; Collins RH; Baer MR; Duong VH; Arellano ML; Stock W; Odenike O; Redner RL; Kovacsovics T; Deininger MW; Zeidner JF; Olin RL; Smith CC; Foran JM; Schiller GJ; Curran EK; Koenig KL; Heerema NA; Chen T; Martycz M; Stefanos M; Marcus SG; Rosenberg L; Druker BJ; Levine RL; Burd A; Yocum AO; Borate UM; Mims AS; Byrd JC; Madanat YF
    Blood Adv; 2024 Oct; 8(20):5297-5305. PubMed ID: 39110987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.